Cargando…
Current development of the second generation of mTOR inhibitors as anticancer agents
The mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, acts as a “master switch” for cellular anabolic and catabolic processes, regulating the rate of cell growth and proliferation. Dysregulation of the mTOR signaling pathway occurs frequently in a variety of human tumors, and...
Autores principales: | Zhou, Hong-Yu, Huang, Shi-Le |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249493/ https://www.ncbi.nlm.nih.gov/pubmed/22059905 http://dx.doi.org/10.5732/cjc.011.10281 |
Ejemplares similares
-
Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016) -
Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016) -
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012) -
mTOR signaling: implications for cancer and anticancer therapy
por: Petroulakis, E, et al.
Publicado: (2006) -
Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)